Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia.

Kibuule D, Aiases P, Ruswa N, Rennie TW, Verbeeck RK, Godman B, Mubita M.

ERJ Open Res. 2020 Mar 16;6(1). pii: 00030-2019. doi: 10.1183/23120541.00030-2019. eCollection 2020 Jan.

2.

Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study.

Adenuga BA, Kibuule D, Bamitale KDS, Rennie TW.

Res Social Adm Pharm. 2019 Nov 18. pii: S1551-7411(19)31094-0. doi: 10.1016/j.sapharm.2019.11.010. [Epub ahead of print]

PMID:
31812500
3.

Optimizing data quality of pharmaceutical information systems in public health care in resource limited settings.

Kagoya HR, Kibuule D, Rennie TW, Wuletaw C, Mitonga KH.

Res Social Adm Pharm. 2019 Sep 13. pii: S1551-7411(19)30599-6. doi: 10.1016/j.sapharm.2019.09.057. [Epub ahead of print]

PMID:
31540878
4.

Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia.

Adenuga BA, Kibuule D, Rennie TW.

Basic Clin Pharmacol Toxicol. 2020 Mar;126(3):247-253. doi: 10.1111/bcpt.13325. Epub 2019 Oct 23.

PMID:
31520574
5.

Health students' knowledge and infectious disease exposure: findings from a cross-sectional study in Namibia.

Rennie TW, Udjombala B, Chipeio M, Kraeker C, Hunter CJ.

Int Health. 2019 Nov 13;11(6):616-618. doi: 10.1093/inthealth/ihz052.

PMID:
31260043
6.

A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia.

Adenuga BA, Rennie TW.

Drug Saf. 2019 Jul;42(7):915-917. doi: 10.1007/s40264-019-00832-3. No abstract available.

PMID:
31069704
7.

Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia.

Kibuule D, Rennie TW, Ruswa N, Mavhunga F, Thomas A, Amutenya R, Law MR, Günther G, Ette E, Godman B, Verbeeck RK.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):441-449. doi: 10.5588/ijtld.17.0785.

PMID:
31064623
8.

Predictors of tuberculosis treatment success under the DOTS program in Namibia.

Kibuule D, Verbeeck RK, Nunurai R, Mavhunga F, Ene E, Godman B, Rennie TW.

Expert Rev Respir Med. 2018 Nov;12(11):979-987. doi: 10.1080/17476348.2018.1520637. Epub 2018 Oct 4.

PMID:
30198358
9.

Distribution of hepatitis B virus infection in Namibia.

Mhata P, Rennie TW, Small LF, Nyarang'o PM, Chagla Z, Hunter CJ.

S Afr Med J. 2017 Sep 22;107(10):882-886. doi: 10.7196/SAMJ.2017.v107i10.12171.

10.

Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.

Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.

Eur J Clin Pharmacol. 2016 Aug;72(8):905-16. doi: 10.1007/s00228-016-2083-4. Epub 2016 Jun 15. Review.

PMID:
27305904
11.

The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.

Verbeeck RK, De Niet S, Lebrun S, Tremege M, Rennie TW, Coffiner M, Streel B, Cahay B.

J Pharm Pharm Sci. 2015;18(1):61-7.

12.

Data mining of tuberculosis patient data using multiple correspondence analysis.

Rennie TW, Roberts W.

Epidemiol Infect. 2009 Dec;137(12):1699-704. doi: 10.1017/S0950268809002787. Epub 2009 May 19.

PMID:
19450381
13.

A pragmatic approach ensuring accuracy in language translation in tuberculosis research.

Rennie TW, Engova D, Bates I.

Res Social Adm Pharm. 2008 Dec;4(4):417-21. doi: 10.1016/j.sapharm.2007.10.007. Epub 2008 Aug 8.

PMID:
19064247
14.

Patient choice promotes adherence in preventive treatment for latent tuberculosis.

Rennie TW, Bothamley GH, Engova D, Bates IP.

Eur Respir J. 2007 Oct;30(4):728-35. Epub 2007 Jul 11.

Supplemental Content

Loading ...
Support Center